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Conclusion

Introduction
Atrial fibrillation (AF) is a common cardiac arrhythmia and a major cause of morbidity and mortality in clinical practice. AF increases the risk of stroke 5Ͳfold and is responsible for at least 20% of all strokes. 1, 2 Until recently, the use of oral anticoagulation with the vitamin K antagonists (VKAs) provided the most effective standard therapy to prevent stroke and systemic embolism in patients with AF, since it reduces the risk of stroke by 64% and allͲcause mortality by 26%, compared to placebo/control. 3, 4 However, the VKAs have important limitations. 5, 6 The variable anticoagulant response, food and drug interactions, and the narrow therapeutic window require close laboratory monitoring and frequent dose adjustments. 7 Poor compliance and/or inadequate anticoagulation control (as reflected by average time in therapeutic range, TTR) can lead to increased adverse events whilst on VKA therapy. 8 Indeed, the TTR can be influenced by many clinical factors, including various comorbidities associated with AF per se. 9 This complicates the management of patients with AF, leading to underuse of VKAs despite the focus of older guidelines on identifying 'high risk'
patients who should be targeted for VKA therapy. 10 In the last decade, several nonͲVKA oral anticoagulants (NOACs) have emerged as potential alternatives to VKAs for the prevention of ischemic stroke and systemic embolism in patients with AF. NOACs previously referred to 'novel' or 'new' oral anticoagulants, but more recently, the terminology became more confusing with Europeans referring to 'direct oral anticoagulants (DOACs)' and North Americans referring to 'target specific oral ancoagulants (TSOCs) in publications and meeting lectures. We have proposed the retention of the acronym NOAC to refer to 'nonͲVKA oral anticoagulants', thereby allowing consistency with older papers. 11 The four NOACs, which include the oral direct thrombin inhibitor, dabigatran, and the oral Factor Xa inhibitors, rivaroxaban, apixaban and edoxaban, have predictable pharmacokinetics, with a stable, doseͲrelated anticoagulant effect and few drug interactions, hence allowing for fixed dosing without the need for regular monitoring of anticoagulation status. 12 Therefore, the management of patients on any of the new agents is distinctly different from that of individuals on warfarin. 13, 14, 15 This review article provides an overview of the four phase III studies (ROCKET AF 16 
Similarities and differences between the NOACs
There are important differences in clinical pharmacology among the four NOACs, with significant implications for their clinical use ( Table 1) . Rivaroxaban, apixaban, and edoxaban are direct factor Xa inhibitors. Dabigatran reversibly inhibits the active site of thrombin (IIa).
Dabigatran etexilate is a proͲdrug that is rapidly converted into the active compound dabigatran by esterases. Dabigatran possesses a lower bioavailability (6.5%) than other NOACs. In summary, dabigatran at a dose of 150 mg bid in the REͲLY study was associated with a lower incidence of stroke and thromboembolism but was similar in the incidence of major bleeding compared with warfarin, whereas dabigatran at a dose of 110 mg bid was associated with a similar rate of stroke and embolic occurrence and a reduced incidence of major bleeding. Intracranial hemorrhage occurred less frequently with rivaroxaban than with warfarin (0.49% vs 0.74% per year; P=0.019). In general, ROCKETͲAF showed that rivaroxaban was nonͲinferior towarfarin in the prevention of stroke or systemic embolism,with no difference in the risk of major and nonͲmajor clinically relevant bleeding. Apixaban was superior to warfarin in the primary outcome of stroke or systemic embolism, with an annual event rate of 1.27% vs. 1.60% (P<0.001 for nonͲinferiority; P = 0.01 for superiority).
ROCKETͲAF
ARISTOTLE
This impressive 21% reduction in the primary endpoint was largely driven by a reduction in hemorrhagic stroke (0.24% vs. 0.47% per year, P<0.001), with no significant difference in the ischemic stroke rate between apixaban and warfarin (0.97% vs. 1.05% per year, P=0.42). Major bleeding events were lower in the apixaban (2.13% vs. 3.09% per year, P<0.001), particularly intracranial hemorrhages (0.33% vs. 0.80% per year, P<0.001). Apixaban was also associated with a lower total mortality rate (3.52% vs. 3.94% per year, P = 0.047). The benefit of apixaban in the primary efficacy and safety outcomes was consistent across all age groups. Thus, the ARISTOTLE study showed that apixaban was superior to warfarin in the prevention of stroke or systemic embolism, and it resulted in less bleeding and lower mortality.
ENGAGE AFͲTIMI 48
ENGAGE AFͲTIMI 48 18 
Comparing the trials, and the different NOACs
A comparison of the main characteristics of the four trials is presented in Table 3 . The studies differed in a number of important respects. ROCKETͲAF, ARISTOTLE, and ENGAGE AFͲTIMI 48
were blinded in both arms, but in REͲLY, warfarin therapy was openͲlabel. In ROCKETͲAF, the mean CHADS 2 score was higher than those in the other three studies, leading to a higher primary endͲpoint event rate (2.4% per year in ROCKET AF vs. 1.6% in ARISTOTLE vs. 1.8% in ENGAGE AFͲTIMI 48 and 1.71% in REͲLY per year, respectively).
In addition, data analyses were not identical. In the ARISTOTLE, ENGAGE AFͲTIMI 48 and REͲLY trials, primary analyses were performed in the intentionͲtoͲtreat (ITT) population. In ROCKETͲAF, this was done as a perͲprotocol analysis and safety was as onͲtreatment analysis.
All four drugs were confirmed to be nonͲinferior compared to warfarin. There was a general trend in favour of study drugs, but the level of significance for superiority was reached only for apixaban and dabigatran 150 mg bid but not for rivaroxaban and edoxaban in the ITT analysis.
Apart for dabigatran 150 mg bid, no study drug showed significantly better ischemic stroke prevention than warfarin, with edoxaban 30mg even resulting in significantly more ischaemic strokes compared to warfarin.
On the safety side, all four new drugs significantly reduced the incidence of hemorrhagic stroke and intracranial hemorrhage. This represents a clear advantage of all four new drugs over warfarin. Interestingly, the REͲLY study initially raised a concern about a numerical increase in the rate of myocardial infarction with dabigatran 150mg bid compared with warfarin (0.74%, 0.53%; P=0.048). A more detailed analysis, including silent myocardial infarctions based on the new appearance of pathological electrocardiographic QͲwaves, did not show significant differences between dabigatran and warfarin. The ARISTOTLE, ENGAGE AFͲTIMI 48,and ROCKETͲAF studies did not corroborate an increase in myocardial infarctions with these drugs.
Although allͲcause mortality was significantly reduced with apixaban and edoxaban 30mg, a similar trend was also observed in the other studies.
Choosing between using a NOAC or VKA
High quality anticoagulation control with VKAs is associated with better efficacy and safety (with low stroke and bleeding risks), and thus, effective stroke prevention in various guidelines with oral anticoagulation refers to use of wellͲcontrolled warfarin (TTR ш70%) or one of the NOACs 22 .
Whilst NOACs generally offer many advantages, a clinical dilemma is how to predict those newly diagnosed nonͲanticoagulated AF patients who would do well on VKA achieving a high TTR, especially given costs of the NOACs and given that the benefits of NOACs over VKAs may be only marginal in those with high TTRs. An ESC position paper 5 recommends use of the new SAMeͲTT 2 R 2 score 9 to aid decisionͲmaking by identifying those AF patients likely to do well on warfarin (SAMeͲTT 2 R 2 score 0Ͳ1) or those more likely to have poor anticoagulation control (SAMeͲTT 2 R 2 score>2). Those patients with a SAMeͲTT 2 R 2 score>2 would probably be better off being started on NOACs as initial therapy, or be targeted for more efforts to improve their anticoagulation control.
Specific patient groups
Renal dysfunction
Patients with AF and renal impairment are at high risk of stroke/thromboembolism, bleeding, myocardial infarction and death. 23, 24, 25, 26 Nonetheless, the net clinical benefit seems to favour use of oral anticoagulation, rather than no anticoagulation. Given the age and comorbidities associated with AF, the presence of normal renal function or even mild renal impairment at baseline does not preclude some patients deteriorating to severe renal impairment. 27 Renal impairment might influence the balance between the safety and efficacy of NOACs (Figure 1) . The various NOACs have different renal elimination characteristics, and this issue may affect the choice of a specific agent. Dabigatran is the drug that is most dependent on the renal function for its elimination and the risk for major bleeding increases with decreasing renal function. For dabigatran 110 mg the annual event rate was 1.53%, 2.89%, and 5.29% for CrClш80, 50-79, and <50 mL/min, respectively, and for the 150 mg dose the corresponding event rates were 2.09%, 3.33%, and 5.44%, respectively. 28 Thus, exposure to dabigatran is increased by renal impairment, and this correlates with the severity of renal dysfunction. Despite a dose reduction, drug accumulation and overdose were initially reported in elderly patients with a low body weight and moderate renal insufficiency, which led to severe and fatal bleeding complications. 29 In those with moderate renal impairment, the lower dose of dabigatran (110 mg) should be used with regular monitoring of renal function. 28, 30 A REͲLY subͲanalysis 31 has demonstrated that the efficacy of both dosages of dabigatran was consistent with the overall trial irrespective of renal function, and the relative reduction of major bleeding with either dabigatran dose compared to warfarin was greater in patients with GFR ш80 mL/min.
The excretion of rivaroxaban and apixaban is only partly dependent upon renal function, and the risk of drug accumulation in patients with renal insufficiency is lower than that observed with dabigatran (Figure 1) . For rivaroxaban, the event rate was 2.06% for a CrCl ш80 mL/min, 2.77% for a CrCl 50-79 mL/min, and 3.37% for CrCl<50 mL/min. 16 For apixaban, the event rate was 1.5%, 2.5%, and 3.2% for normal renal function, mild impairment, and moderateͲsevere impairment, respectively. 17 Both drugs can be administered at fixed doses in patients with moderate renal impairment, and the current prescribing label for both drugs allows its use if creatinine clearance is ш15 mls/min. For apixaban, a recent analysis clearly shows the safety of this drug with moderate renal impairment, whilst retaining superior efficacy. 32 Although the ENGAGE AFͲTIMI 48trial has yet to formally publish data regarding the event rate of bleeding in patients with renal impairment, edoxaban is also partly dependent on renal function (50% renal excretion).
In summary, we should check renal function in all patients before choosing one of the NOACs and should not give any NOACs to patients with severe renal impairment (CrCl< 30 mL min). In patients with moderate renal impairment (CrCl 30-50 mL min),although dabigatran 110 mg bid and rivaroxaban can be used, apixaban is probably the safer option, particularly in elderly patients with a low body weight (<60kg).
Elderly patients
While AF is uncommon in patients below 65 years of age (<2%), the prevalence is approximately 10% in patients aged 85 years or over. 33 Due to the higher incidence of stroke in the elderly, the absolute risk reduction is higher in elderly than in younger patients. 34 Oral anticoagulation is beneficial in the elderly with a superior reduction in stroke and no significant difference in major bleeding between warfarin and aspirin. 35 Regardless of high stroke risk and a greater net clinical benefit from oral anticoagulation, elderly patients with AF (aged >75-80 years) are often denied warfarin owing to the perception of a substantially increased bleeding risk in the presence of multiple comorbidities, impaired renal function, or cognitive impairment. 36 However, due to a lower tendency for food and drug interactions, the anticoagulant effects of NOACs are much more predictable than VKAs, allowing them to be given in fixed doses without routine coagulation monitoring.
The NOACs have many benefits over warfarin for stroke prevention in patients with AF in the elderly. Treatment decisions also require an assessment of the practical considerations associated with these treatments, including the need for dose adjustment in specific patients, costͲeffectiveness, limitations in monitoring the extent of anticoagulation, and the lack of specific reversal agents. Such considerations are particularly important in the treatment of older patients, who may experience different reactions to drugs than younger patients. This is often due to older patients having poor renal clearance, a lower body weight, and polypharmacy. 37 Data from the phase III randomized, controlled trials all confirm that the absolute risks of both thrombotic events and bleeding rise with advancing age. For instance, patients aged over 75 years represented 43.1%, 31.2%, 40.2%, and 40.1% in the ROCKETͲAF, ARISTOTLE, ENGAGE AFͲTIMI 48, and REͲLY studies, respectively. In ROCKETͲAF, the efficacy and safety of rivaroxaban appears to be consistent across age categories. In the various trials with rivaroxaban, apixaban and edoxaban, no interaction with age was reported for the efficacy outcome and the occurrence of major bleeding. In the REͲLY study, however, a highly significant interaction between age and major bleeding was found (Figure 2 ).
Racial differences
The ageͲadjusted prevalence of AF may be lower among Asians than among Caucasians. 33 However, the prevalence and incidence of arterial thromboembolism may differ from those of European and American countries. 38 Specifically, Asian patients have a fiveͲtoͲsixͲfold higher stroke risk than Caucasians, but anticoagulation therapy is not commonly given to Asian patients with nonͲvalvular AF, probably because of the (perceived) risk of critical bleeding, which might be higher in Asian patients. Indeed, warfarinͲrelated intracranial hemorrhage in Asian patients was reported to be 1.75 per 100 patientͲyears, which is significantly higher than that in Caucasians (0.34 per 100 patientͲyears). 39 This is further complicated by the difficulty of maintaining a therapeutic international normalized ratio when using VKAs. These challenges might explain why VKAs are underused by physicians who treat patients in Asia. 40 Moreover, in Asians, the risk of stroke and systemic embolism for warfarinͲanticoagulated AF patients appears to be higher compared to NonͲAsians, though Asians had similar mean CHADS 2 scores. 41 Indeed, in the REͲLY Asia subͲanalysis 42 ). These data would suggest that trial investigators in Asia tended to keep an INR in the lower range, perhaps to avoid bleeding. Both bleeding and thromboembolism rates are generally higher in Asians compared to nonͲAsians, and therefore warfarin is difficult to manage properly in Asians.
The NOACs may provide a safe, effective, and convenient alternative to warfarin, especially in Asians (the Asian subͲanalysis of edoxaban are awaited). The Asian subgroup analysis of the REͲLY trial demonstrated superiority of dabigatran 150 mg bid over warfarin in reducing thromboembolism. Also, the risk of major bleeding in the group of dabigatran 150 bid was significantly lower than the warfarin group in Asians, with a greater relative risk reduction than that from nonͲAsians. Indeed, the annual risk of major bleeding in dabigatran 150 mg bid group was 2.17% for Asians and 3.52% for nonͲAsians. The annual risk of major bleeding in dabigatran 110 mg bid group was 2.22% in Asians and 2.99% in nonͲAsians. In the Asian subͲgroup analysis of the ARISTOTLE trial 43 , apixaban had consistent benefits when compared with warfarin for stroke or systemic embolism in East Asian and nonͲEast Asian patients. The annual risk of major bleeding from apixaban was 2.02% for Asians and 2.15% for nonͲAsians. The rate of stroke and systemic embolism from the East Asia cohort of the ROCKETͲAF study were consistent with those of the main study. The annual risk of major bleeding from rivaroxaban was 4.9% for Asians and 7.6% for nonͲAsians.
The use of NOACs in patients with AF in Asia provides an opportunity for improved quality of care, since the rate of both thromboembolism and bleeding risk associated with NOACs was consistent with that observed globally. A modeling exercise suggests how use of NOACs may lead to a major impact on the burden of AFͲrelated stroke in China. 44
Combination of nonͲVKA oral anticoagulants and antiplatelet therapy
The management of antiplatelet and anticoagulant therapy is challenging in patients with AF who sustain an acute coronary syndrome and/or undergo percutaneous coronary intervention/stenting, or in patients with coronary artery disease who develop AF. The optimal strategy to provide adequate antiplatelet and anticoagulant therapy is currently unclear.
Observational data have shown an increased risk of bleeding after treatment with antiplatelet therapy together with an anticoagulant "triple therapy." 45, 46 A subͲanalysis of the REͲLY trial showed an increased risk of bleeding and thromboembolic events associated with antiplatelet therapy compared with no antiplatelet therapy and consistent treatment effects when compared with warfarin, regardless of aspirin use. 47 Both the ATLAS ACS 2ͲTIMI 51 48 and APPRAISEͲ2 49 trials confirmed a doseͲdependent increase in major bleeding events, including intracranial bleeding, with rivaroxaban and apixaban when they were combined with dual antiplatelet therapy (DAPT).
In the ATLAS ACS 2ͲTIMI 51, lowͲdose (2.5 mg bid) rivaroxaban was associated with a significantly lower composite of cardiovascular death, myocardial infarction, or stroke (the primary efficacy endpoint), compared to placebo. Of note, the doses were 2.5 or 5 mg bid, which correspond to oneͲfourth and oneͲhalf, respectively, of the dose tested in AFpatients. 16 In APPRAISEͲ2, however, the primary safety outcome of major bleeding occurred more often with apixaban than with the placebo. Apixaban was associated with more intracranial hemorrhage and with a numerical increase in fatal bleeding. Consequently, the trial was terminated prematurely before completing enrollment of the planned patients considering the overall efficacy/safety balance.
In summary, the need for NOACs in combination with DAPT should be critically assessed, and the duration of combined therapy minimized. The duration of DAPT is determined by the risk of bleeding, type of stent and the perceived risk of stent thrombosis. The use of thirdͲgeneration drug eluting stents may reduce the time DAPT is required to prevent stent thrombosis.
Patient's values and preferences
Patient's preferences for OAC therapy should be an integral part of the treatment decisionͲmaking process, 50 as advocated by current clinical guidelines. 22 To enable patients to make informed choices about whether or not to initiate OAC and to allow them to choose between the available OAC drugs requires the patient to be appropriately educated about their own individual risk of stroke (hence the need for OAC) and their risk of major bleeding associated with the different OACs. The responsibility for educating AF patients and allowing them to voice their preferences for OAC treatment lies with the treating clinician. 51 A recent study by LaHaye and colleagues 52 used an iPad to present patients with their individual risk of stroke (using CHA 2 DS 2 ͲVASc) and bleeding with treatment, using a variety of different formats and elicited their preferences for antithrombotic therapy. This study corroborates previous research 50 which reports that patients are more concerned about the risk of stroke than the risk of bleeding; patients were prepared to suffer 4.4 major bleeds in order to prevent one stroke. 52 Involving patients' in discussions about treatment options and eliciting their preferences provides clinicians with the opportunity to educate patients about AF and the risks and benefits of treatment, to correct or allay misconceptions patients may hold about OAC, identify and overcome barriers to adherence, and improves the likelihood of arriving at a mutually agreeable treatment decision. 51
Conclusion
This overview has several limitations. First, each phase III trial examined different NOACs and there was important heterogeneity regarding study designs and included populations. Second, patients taking warfarin in realͲlife clinical practice are less likely to be in a therapeutic range than those in controlled studies. Therefore, further insights into the appropriate use of these agents will become apparent when they are used in 'realͲworld' clinical settings, and some initial data from postͲmarketing studies do suggest that these drugs appear safe compared to warfarin when used in newly diagnosed anticoagulation naïve patients. 53, 54 Some reports suggest need for caution amongst 'switchers' from warfarin to NOACs, and a high rate of bleeding and thromboembolism was observed. 55 It is worth emphasizing that these drugs are powerful anticoagulants that offer efficacy and safety compared to warfarin if used correctly according to guidelines and/or prescribing recommendations. 56 The introduction of 4 new NOAC alternatives for anticoagulation represents a major step forward in improving outcomes and quality of life. Compared with VKAs, these new alternatives have important advantages, such as lower risk of intracranial bleeding, no clear interactions withfood, favorable pharmacokinetic profiles, and no need for routine monitoring. Indeed, these new oral anticoagulants will be preferred alternatives to VKAs for many patients with AF and an increased risk of stroke. Modelling analyses clearly show the potential healthcare and public health impact of NOACs in reducing the burden of stroke in patients with AF. 57, 58 Things can only get better. 
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